Hearing disorder in HIV positive adult patients not on Anti - Retroviral  drugs at Kenyatta National Hospital by Oburra, HO
September 2010 East african MEdical Journal   385
East African Medical Journal Vol. 87 No.9 September 2010
HEARING DISORDERS IN HIV POSITIVE ADULT PATIENTS NOT ON ANTI-RETROVIRAL DRUGS AT 
KENYATTA NATIONAL HOSPITAL.
B. A. Ongulo, MBChB, MMed (ENT Surg) Nbi, ENT Surgeon, Armed Forces Memorial Hospital, P. O Box 
1341-00100, Nairobi and H. O. Oburra, MBChB, MMed (surg Nbi), FRCSE, Associate Professor and Chairman, 
Department of Surgery, College of Health Sciences, University of Nairobi, P.O. Box 42086-00100, Nairobi, 
Kenya. 
Request for reprint to: Dr. B. A. Ongulo, ENT surgeon, Armed Forces Memorial Hospital P. O Box 13419-
00100 Nairobi, Kenya
HEARING DISORDERS IN HIV POSITIVE ADULT PATIENTS NOT ON ANTI - 
RETROVIRAL DRUGS AT KENYATTA NATIONAL HOSPITAL. 
B. A. ONGULO and H. O. OBURRA
AbSTRAcT 
Objectives: To determine the prevalence and type of hearing disorders in HIV positive 
patients not on anti - retroviral drugs (ARVs) and correlate this with the world health 
Organization (WHO) stage of HIV disease and cD4 positive cell counts.
Design: case control study.
Setting: comprehensive care clinic (ccc) and Voluntary counseling and testing 
centre at Kenyatta National Hospital.
Subjects: One hundread and ninety four HIV positive patients attending ccc and 
124 HIV negative subjects recruited from voluntary counseling and testing (VcT) 
centre.
Results: Hearing loss (HL) was present in 33.5% of HIV positive compared to 8.1% in 
negative subjects. No gender bias in HL Sensorineural hearing loss (SNHL) was the 
most common and the frequencies most ‘affected were four and eight kHz 
conclusion: Hearing loss is more prevalent in HIV positive individuals not on 
anti - retroviral drugs than negative normal subjects. Low cD4 cell count and advanced 
HIV diseases were associated with increased chance of having a hearing loss. Otological 
care should be part of the comprehensive care of HIV positive patients.
INTRODUcTION
Over 50% of HIV infected patients present 
first to the otorhinolaryngologist (1). Of all the 
otorhinolaryngological manifestations, otological 
symptoms comprise at least 62% (2), Somefun 
et al’ looked at 98 patients at Lagos University 
teaching hospital and found that while only 
17% of the patients were referred because of 
otorhinolaryngological diseases, 80% of them 
actually had otorhinolaryngological, head and neck 
conditions (3).
 Infections with either pneumocystis or 
mycobacterium tuberculosis can result in a tumour-
like lesion in the external auditory canal (4) and can 
enlarge to occlude the entire canal (5). External ear 
infections in the HI V-infected patients have the same 
pathophysiology as in the immunocompetent patients 
(6) but seborrheic dermatitis of the external ear may 
present with recurrent superinfections of the involved 
skin (7). Serous otitis media and recurrent acute otitis 
media frequently affect paediatric patients with HIV 
disease because of eustachian tube dysfunction which 
results from nasopharyngeal lymphoid hyperplasia, 
sinusitis, nasopharyngeal neoplasm or allergies (2). 
Primary infection by HIV of either the CNS or 
the peripheral auditory nerve results in increased 
latencies on auditory brain stern testing suggesting 
central demyelination consistent with a viral infection 
(8). When vertigo occurs in HIV infected patients, 
it is together with a multitude of other neurologic 
symptoms and it is frequently a symptom of subacute 
encephalitis or HIV dementia complex (6).
 Numerous international studies have 
demonstrated a relationship between HIV/AIDS 
and auditory function. Kohan et al conducted a five 
year retrospective study to evaluate otologic disease 
in patients with AIDS at New York university medical 
center- Bellevue hospital. They found that 62% had 
hearing loss (2). Marra et al. did a case control study 
of nine HIV positive patients at the university of 
Washington HIV based clinic and found that 29% of 
the patients had hearing loss (9). 
 Hearing disability compromises the overall 
economic productivity of an individual and may 
render one an outcast (10). In this study, the nature 
and degree of hearing disability in HIV-infected 
patients presenting at CCC were determined.
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MATERIALS AND METHODS.
This was an hospital based case control study done 
between January and April 2007, at the comprehensive 
care clinic and voluntary counselling and testing 
centre. A minimum sample size of 115 was required 
in each arm. The study subjects were aged 18 to 50 
years and were HIV positive at various stages of the 
HIV disease but not on anti-retroviral drugs. The 
controls were HIV negative subjects matched for age 
and sex recruited from VCT centre. 
 A clinical history was taken followed by thorough 
physical examination, otoscopy and tuning folk 
tests. Pure tone audiometry (PTA) was done using a 
calibrated clinical computer audiometer model Ac5 
in a sound proof-insulated room starting with 1000 
hertz (Hz) followed by 2 KHz, 4 KHz, 8 KHz, 500Hz. 
and 250Hz in that order. Subjects who had hearing 
level of more that 25 decibels were categorised as 
having a hearing loss.The WHO staging of the HIV 
disease and CD4+ cell count were carried out in the 
study subjects. CD4+ count was determined by the 
automated flow cytometry analyser, FASCOUNT 
(Becton Dickinson international, USA). Patients 
who suffered diabetes, meningitis, head injury or 
cerebrovascular accident, wax impaction and those 
who had exposure to ototoxic medications as well 
as those who had excessive exposure to noise were 
excluded from the study or as control subjects, Data 
analysis was done using SPSS version 10.0 software 
and descriptive statistics were done.
 Approval was obtained from the Ethics and 
Research committee of Kenyatta National Hospital. 
RESULTS 
The study group comprised of 194 subjects who were 
HIV positive but not on ARV s and the control group 
were 124 subjects who were HIV negative. In the 
study group, males were 75 (38.7%) while females 
were 119 (61.3%) giving a ratio of 1:1.59. In the control 
group, males were 47 (37.9%) and females were 77 
(62.1 %) giving a ratio of I: 1.16. Most of the patients 
were between 32 to 38 years old. 
Table 1 
Age statistics. 
Age(Years) Study group or HIV+ Control or HIV -
18-24     8 5
25-31      50 30
32-38      65 42
39-45      38 26
46-50      33 21
Mean     36.1 36.4
Median     35 36
Mode     37 37
Figure 1 
Gender distribution in the study and control groups. 
In the study group, 33.5% of the patients had hearing 
loss compared to only 8.1% in the control group 
(table 2). 
Table 2
 Hearing level in the study group and control group. 
    Hearing level   Total
 Hearing loss Normal hearing
Study Group    65.0 129.0  194.0
Percentage(%)  33.5 66.5  100.0
Control    10.0 114.0 124.0
Percentage (%) 8.1 91.9  100.0
 The subjects in the study population with a 
hearing loss comprised 40 females representing 33.6% 
of the females and 25 males representing 33.3% of the 
male population (figure 2). There was no gender bias 
in hearing level. 
Figure 2
Gender and hearing level 
The study subjects were grouped into age sets and 
their hearing level determined. There was a trend of 
worsening hearing level with increase in age (figure 
3) and this was statistically significant p=0.022. 
 The subjects were classified according to the 
WHO clinical staging for retroviral disease and 
the hearing level determined. Results indicate that 
hearing loss was worse in advanced disease (figure 
4) and this was statistically significant p=0.003. 
Figure 3
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Relationship between hearing level and age. 
Figure 4
Relationship between WHO stage and hearing level.
 The HIV positive patients were grouped into 
the CDC laboratory categories according to the 
CD4 positive lymphocyte counts and the hearing 
levels correlated. A higher percentage of patients in 
laboratory group C had hearing loss at 38% followed 
by group B at 28% and group A at 22% (figure 5). 
The absolute CD4 positive cell count was found to 
be related to the development of a hearing loss.
Figure 5
Relationship between CDC stage and hearing level. 
 When the nature of hearing loss was assessed, 
it was found that 74% had SNHL, 22% conductive 
hearing loss (CHL) and 4% had mixed hearing loss. 
Mild hearing loss (70%) was the most common 
followed by moderate hearing loss (24.5%), moderate 
severe (4.5%) and severe (1 %). The frequency most 













Hearing loss is a cardinal feature and disability in 
HIV/AIDS patients (2, 9,11,12). In this study, 33.5% 
of HI V positive patients not on ARVs had hearing 
level above 25 dB compared to only 8.1 % in HIV 
negative normal subjects. Soucek and Michaels got 
39% in a sample size of 65 subjects (11) and Wang 
et al got 45.5% in a sample size of 350 (12). There 
is a wide variation found in different studies and 
this could be due to the sample size and the cut of 
decibel for hearing loss but they consistently showed 
hearing loss in the HIV positive patients. 
 This study found no difference in the HL 
according to gender. This suggests that the sex of the 
subject does not playa major role in the causation 
of hearing loss. 
 The HL gets worse with advancement of age 
and this was found to be statistically significant 
P<0.05 (0.022). Marra et al also got a similar finding 
(9). In this study, patients over 50 years of age were 
excluded to avoid the effects of presbyacusis. The 
older subjects in this study comprised the majority 
with HL compared to the younger population; 
however, it is not clear whether this due was to HIV 
infection (13) or other factors related to aging.
 The number of subjects with a HL increases with 
advancement in the WHO stage of the disease. This 
was statistically significant and it could have been 
due to the effect of the HIV virus on the cochlear 
(14), middle ear infections (15) or CNS complications 
(11). Patients with advanced HIV disease are more 
predisposed to infections including those that 
interfere with hearing. Michaels et al found that 60% 
of patients who succumbed to HIV had features of 
otitis media in their temporal bones (15). Subjects 
with CD4+ cell counts below 200/µ1 had the highest 
proportion of those with HL at 38%, followed by 
those with CD4 cell counts between 200 and 500/µ1 
at 28% and those whose CD4 cell counts were above 
500/µ1 at 22%. Kohan and Giacchi’s findings were 
similar in that more immunocompromised patients 
had more advanced otologic disease (16). 
 SNHL was the most common type of HL at 
74% followed by CHL (21.5%) and mixed HL (4.5%). 
Mild HL was the most common at 70% followed by 
moderate HL (24.5%), moderate severe HL (4.5%) 
and severe HL was 1%. A similar pattern was seen 
in a study by Soucek (11). 
 The higher frequencies (4 KHz and 8 KHz) 
were the most affected while the middle frequencies 
are largely spared. Similar findings were gotten 
by Soucek where 6 KHz and 8 KHz were the most 
affected. This is thought to be due to changes in the 
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 The possible causes of HL in HIV disease could 
be divided into three, those due ototoxic drugs 
administered to these patients, direct effects of the 
virus to the CNS and opportunistic infections and 
tumours in the CNS, and lastly the effects of the virus 
on the cochlear (15). 
In conclusion hearing loss is more prevalent in 
HIV positive individuals. This indicates that the 
HIV positive patient may not be able to follow the 
instructions and counseling usually given as part 
of the comprehensive care and this may negatively 
impact on the overall care and quality of life. 
 HIV positive patients frequently do not complain 
of deafness until significant hearing loss has occurred. 
They usually have many symptoms and initially may 
perceive hearing loss as a relatively minor problem 
in comparison or may actually think it is part of the 
disease problem (10). Therefore, clinicians should 
deliberately seek to find out the hearing level of these 
patients for early and timely remedial measures. 
Patients with a low CD4+ cell count and advanced 
WHO stage of HIV disease are likely to develop a 
hearing loss before commencement of ARVs. 
 SNHL is the most common type of hearing 
disorder in HIV positive individuals and the intensity 
of the hearing loss is mostly mild. The higher 
frequencies are the most affected followed by the 
lower frequencies while the middle ones are largely 
spared (11). 
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